key: cord-0846122-m71wnwnv authors: Ashktorab, Hassan; Pizuorno, Antonio; Aduli, Farshad; Laiyemo, Adeyinka O.; Oskrochi, Gholamreza; Brim, Hassan title: Elevated liver enzymes, ferritin, CRP, D-dimer, and age are predictive markers of outcomes among Covid-19 African Americans and Hispanic patients date: 2021-03-31 journal: Gastroenterology DOI: 10.1053/j.gastro.2021.03.043 sha: 31790f77e29839a0a38040d517169ed0b6e48b41 doc_id: 846122 cord_uid: m71wnwnv nan Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused a worldwide outbreak. Its associated disease COVID-19 causes respiratory, gastrointestinal (GI), inflammatory and neurological symptoms 1 . In the US, minorities such as African Americans (AA) and Hispanics (HSP) have shown a higher incidence of the disease 2, 3 . However, no detailed characterization of the disease's features in these populations have been performed 4 . While the initial focus was on saving lives, and developing and delivering vaccines and therapeutics, the focus is shifting towards an assessment of specific features of the disease in different patients' groups, variables that affect outcome and more importantly factors that correlate with persistent and recurring symptoms 5 . In this study, we describe the demographics, clinicals and gastrointestinal symptoms of hospitalized minority patients with confirmed SARS-CoV-2 infection at a tertiary hospital located in Washington D.C. We also sought to determine how these features relate to outcome and which can be considered for prognosis assessment. A list of 447 hospitalized adults (March to September 2020 at Howard University Hospital) COVID-19 patients was obtained. This study was approved by the Institutional Review Board. Demographics, clinicals, comorbidities, laboratory test results and treatment data were collected from the patients' charts, Statistical analysis Patients' demographics, symptoms, comorbidities, treatment and clinicals' relation to outcome was assessed in the overall cohort and in subgroups analysis of AA, Caucasians (CAU) and HSP. Correlation coefficients were calculated together with multivariate binary logistic regression analysis to establish associations with death as an outcome. SPSS ver. 26 (SPSS Inc., Chicago, IL) was used for these analyses. Overall features of the cohort: Our cohort consisted of 447 patients with 309 (69.1%) AA, 27 (6%) CAU, and 111 (24.8%) HSP with overall 71 deaths (15.5%). AA and CAU had similar death rates, 18.1% and 18.5%, while HSP had 7.3% deaths. The overall age was 56.1 years, with 53.9 for survivors versus 68.6 for those that died. HSP were the youngest with 44.9 years old while CAU were the oldest with 61.1 years old. There were 51.1% males and 48.9% females. Our cohort had an average BMI of 30.6 and HSP had the lowest BMI with 27.4 versus AA with 31.6 ( Table 1) . Overall diarrhea was the most common GI symptom with 19.4% followed by abdominal pain in 15.8%. GI bleeding was reported in 4.4%, pancreatitis in 0.9%, and cholecystitis in 1.6%. Diarrhea frequency was highest in AA with 22.4% while abdominal pain was highest in HSP with 17.3%. Worth noting that 24% of the overall cohort presented these GI manifestations after admission. The most common comorbidities in our study were hypertension with 55.2% followed by diabetes in 38.4% and cardiac disease in 20.2%. With respect to GI comorbidities, the most common was history of liver disease (4.3%) and history of GERD in 10%. HSP had the lowest level of pre-existing liver disease, while CAU had the highest rate of GERD/PUD history (15.3%), only 1.3% AA had a previous diagnosis of Inflammatory Bowel Disease (Table 1) . Overall, 41% of our cohort had abnormal levels of liver function test panel. CAU had the highest proportion of such patients (52.1%). Elevated ALT was reported in 77.1% of tested patients, this rate was the lowest in CAU (33.3%). Elevated AST was reported in 50% and was highest in CAU (66.7%). Other abnormal test results were elevated D-dimer in 89%, abnormal IL-6 in 99.2% and elevated Ferritin in 61.9% (Table 1) . Variables' correlations with death as an outcome: Older age (p<0.001), shortness of breath (p<0.001), abdominal pain (p=0.050), GI bleeding (p=0.009), diabetes (p=0.021), elevated Ferritin (p=0.02), D-dimer (p=0.008), CRP (p<0.001), elevated Procalcitonin (p<0.001), elevated Creatinine (p<0.001), altered platelet (p=0.002), high LFT on admission (p<0.001), pneumonia (p<0.001), ICU admission/transfer (p=<0.001), sepsis (p=<0.001), vasopressors (p<0.001), mechanical ventilation (p<0.001) were statistically associated with death in the overall cohort (Supplemental Table 1 ). For AA, shortness of breath (p=0.032), elevated ferritin (p=0.004), D-dimer (p=0.031), CRP (p<0.001), Procalcitonin (p<0.001), LFT on admission (p<0.001), pneumonia (p=0.007), ICU admission (p=<0.001), ICU transfer (p<0.001), sepsis (p<0.001), vasopressors (p<0.001), mechanical ventilation (p=0.020) were significant associated with death (Table B) . As for HSP, shortness of breath (p=0.008), GI bleeding (p=0.001), hypertension (p=0.031), elevated Procalcitonin (p=0.003), elevated Triglycerides (p=0.004), pneumonia (p=0.048), ICU admission (p=0.004), ICU transfer (p<0.001), sepsis (p=0.004), ECMO (p=0.020), vasopressors (p<0.001), Remdesivir (p=0.043), mechanical ventilation (p<0.001) were associated with death as an outcome (Supplemental Table 1 ). For CAU, only associated with death were diabetes (p=0.018), hypertension (p=0.049), elevated Procalcitonin (p=0.009), mechanical ventilation (p=0.023) and vasopressors (p=0.033; Supplemental Table 1 ). In the overall cohort analysis, age was a major effector of outcome. This was further confirmed in subgroup analyses. Indeed, HSP the youngest group had the lowest death rate while CAU the oldest had the highest death rate. Respiratory issues such as shortness of breath, and pneumonia requiring ICU care and mechanical ventilation were strongly associated with poor outcome in our patients, regardless of race. Elevated Procalcitonin was also a common risk factor. Procalcitonin is primarily increased in response to bacterial-triggered inflammation pointing to potential opportunistic pathogens' activity in the course of COVID-19. Vasopressors' use in critically ill patients was also associated with poor outcome, attesting to unstable hemodynamics independently of race 6 . Diabetes' association with poor outcome was noted in CAU only, while hypertension was common with HSP. This finding reflects the weight of metabolic syndrome in CAU that were the oldest group J o u r n a l P r e -p r o o f in our cohort. The small number of CAU in our cohort is a limitation of the study. Within HSP, high triglycerides level was a risk factor reflecting the negative impact of blood fat in CAD and outcome. While HSP had a lower BMI, in comparison to AA, the cumulative effects of high triglyceride levels and hypertension point to the impact of the metabolic syndrome in this group, even though it was the youngest. GI bleeding was reported as a risk factor in HSP as well. Whether this symptom is a cause or consequence risk of hemodynamic instability remains to be explored. Indeed, such cases were reported in patients with thromboembolism 7 . Elevated ferritin, D-dimer, and CRP were major and unique risk factors to AA in the subgroups analysis highlighting the prevalence of systemic inflammation and coagulopathies in this group. Worth noting that elevated LFTs on admission were significantly associated with poor outcome in our study cohort. A study reported that chronic liver disease patients were more likely to develop severe COVID-19 8 . However, liver function alterations were also reported as a result of COVID-19 or anti-viral treatment during hospitalization. Diarrhea frequency and abdominal pain were highest in AA and HSP, respectively. They are likely to affect post-discharge patient's condition as the virus persists longer in the GI tract after clearance from the respiratory system. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis Racial Disparity in Gastrointestinal Cancer Risk Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations Insights into disparities observed with COVID-19 Covid-19: US cases surge but vaccine distribution is slow Critically ill patients with COVID-19: are they hemodynamically unstable and do we know why? Post COVID-19 sequelae: venous thromboembolism complicated by lower GI bleed Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection